#21 - Tom Dayspring, M.D., FACP, FNLA – Part II of V: Lipid metrics, lipid measurements, and cholesterol regulation

Episode Summary

Executive Summary: This episode explains lipoprotein biology from first principles: how hydrophobic lipids travel in blood, why particle density reflects lipid-to-protein ratio, and why ApoB/LDL particle number better capture atherosclerotic risk than LDL-C alone. It also covers cholesterol/sterol chemistry, absorption and efflux pathways, reverse cholesterol transport, and why many common lipid metrics are misused clinically.

Main Topics: Lipoprotein basics and density (Priority: 5/5): Explains why lipids require lipoproteins for transport in plasma, how ultracentrifugation revealed different lipoprotein densities, and why smaller particles are denser because they contain relatively more protein and less lipid. ApoB, LDL-C, and particle number (Priority: 5/5): Distinguishes LDL cholesterol from LDL particle number and ApoB, arguing that ApoB/LDL-P are better proxies for atherogenic burden and clinical risk than LDL-C, especially when metrics are discordant. Measurement history and lab methods (Priority: 4/5): Reviews the evolution from total cholesterol assays to HDL direct assays, Friedewald-calculated LDL-C, direct LDL-C, and NMR-based particle counting, including limitations at higher triglycerides. Sterol chemistry and terminology (Priority: 4/5): Defines sterane, sterol, stanol, cholesterol ester, phytosterols, and explains how small structural changes alter absorption, transport, and biological function. Cholesterol synthesis and tissue-specific use (Priority: 4/5): Describes de novo cholesterol synthesis from acetyl-CoA through lanosterol and downstream pathways, and emphasizes that cholesterol is used for membranes, steroid hormones, and bile acids—not energy. Absorption, efflux, and reverse cholesterol transport (Priority: 5/5): Covers intestinal sterol uptake via NPC1L1, export via ABCG5/G8 and ABCA1, and the role of transintestinal cholesterol efflux (TICE) as a major route of cholesterol disposal. Clinical implications and discordance (Priority: 5/5): Highlights that lipid panels can be misleading in acute illness and that clinicians should assess ApoB or LDL-P, especially when LDL-C and particle metrics disagree.

Key Arguments: Lipids generally cannot circulate freely in plasma; they travel inside lipoproteins or on carrier proteins like albumin. Atherosclerosis requires delivery of sterols into the arterial wall, and ApoB-containing particles are the main vehicles responsible. Particle number matters more than cholesterol content because many small LDL particles can carry the same cholesterol load as fewer large particles while posing greater risk. LDL-C is a surrogate for particle burden, not a direct measure of atherogenic particles; ApoB or LDL-P is more informative. Non-HDL cholesterol is a better poor-man’s proxy for ApoB than LDL-C, and direct LDL-C is preferable to calculated LDL-C when triglycerides are elevated. Phytosterols are not benign supplements; evolution appears to have limited their absorption and export, suggesting potential toxicity in hyperabsorbers. Cholesterol is essential for membranes and hormone synthesis but is not used as an energy source. Blood lipid values are snapshots of plasma flux and do not directly reveal intracellular cholesterol status or tissue needs. Reverse cholesterol transport is not solely HDL-mediated; TICE is a major pathway for cholesterol elimination. In acute inflammatory states, HDL-C can fall dramatically because cholesterol is being mobilized for steroidogenesis and stress responses.

Data Points: Total cholesterol assay era: Late 1940s to early 1950s - Discussed as the period when clinical cholesterol measurement became available. Albumin cholesterol carrying capacity: ~17 molecules of cholesterol - Used to illustrate albumin as a carrier of lipids in blood. APOB48 molecular weight: 48% of APOB100 - Intestinal APOB isoform compared with hepatic APOB100. APOB31 molecular weight: 31% of normal APOB - Example of a genetic APOB variant. VLDL cholesterol estimate: Triglycerides ÷ 5 - Friedewald-style approximation used to calculate LDL-C from total cholesterol, HDL-C, and triglycerides. Triglyceride threshold for caution: >150-200 mg/dL - Calculated LDL-C becomes less reliable as triglycerides rise. Triglyceride threshold where formula is poor: >400 mg/dL - Older guidance noted calculated LDL-C should not be used at very high triglycerides. LDL particle contribution to ApoB pool: ~95% - Most ApoB particles in circulation are LDL particles. HDL half-life: ~5 days - Described as a circulating cholesterol reservoir for steroidogenic tissues. TICE contribution to cholesterol disposal: ~20% to 60% - Reported range for transintestinal cholesterol efflux contribution in humans. Cholesterol carbon count: 37 carbons - Used in the synthesis discussion of cholesterol structure. Cholesterol structure: 4-ring sterol nucleus with OH at carbon 3 - Explained as the defining chemical structure of cholesterol. Chylomicron half-life: Minutes - Used to explain why NMR particle counts are dominated by VLDL rather than chylomicrons in most settings.

Pivotal Quotes: "lipids, for the most part, go nowhere in the human body unless they're a passenger inside a lipoprotein." — Tom Dayspring: Core principle of lipid transport and the reason lipoproteins matter clinically. "the only value that calculated or directly measured LDL cholesterol brings to the table is it's a better poor man's estimate of your LDL particle concentration than is total cholesterol." — Tom Dayspring: Explains why LDL-C is a surrogate rather than the best risk metric. "the body can get rid of cholesterol without a biliary system." — Tom Dayspring: Used to emphasize the importance of transintestinal cholesterol efflux (TICE).

Implications: Listeners should prioritize ApoB or LDL-P over LDL-C alone, especially when results are discordant. For clinicians, the episode argues for more precise lipid testing, better education, and less reliance on outdated metrics and assumptions.